The Journal of dermatological treatment · 2026
5-Aminolevulinic acid-based photodynamic therapy used as a long-term management approach for refractory lichen sclerosus.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qian Yitao, Zha Wenjing, Shen Jie, Li Ke, Zhang Shimin, Yu Yiwu, Huang Jianhua, Lyu Ting, Miao Fei, Chen Qianyi, Wang Yijing, Wang Hongwei, Shi Lei
Аннотация
OBJECTIVES: To report the long-term clinical response and tolerability of repeated 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) in a patient with refractory male genital lichen sclerosus (LS).
METHODS: A 37-year-old man with a history of genital LS lasting more than 10 years experienced recurrence after surgical resection, which had resulted in permanent anatomical deformity. He received multiple courses of ALA-PDT, including intensive and maintenance treatment, over five years.
RESULTS: Symptoms and lesions were well controlled after 13 initial ALA-PDT sessions. However, the lesions recurred after ALA-PDT was discontinued and topical halometasone was introduced. The patient subsequently received further courses of ALA-PDT, bringing the total to 41 sessions. Lesions regressed following each treatment course. Adverse effects were mild and tolerable, and no severe adverse events were observed over the five-year period. No recurrence was noted during the one-year follow-up after the final treatment course.
CONCLUSIONS: This case suggests that repeated ALA-PDT may be an effective and well-tolerated option for the long-term management of refractory male genital LS. Therefore, this patient underwent multiple courses of ALA-PDT for a total of 41 sessions With each course of ALA-PDT, the lesions regressed again, and no significant adverse effects were observed over the five-year period. No recurrence was noted during the one-year follow-up after the final treatment course. This case indicated ALA-PDT may be a safe and effective option for the long-term management of male genital LS.
METHODS: A 37-year-old man with a history of genital LS lasting more than 10 years experienced recurrence after surgical resection, which had resulted in permanent anatomical deformity. He received multiple courses of ALA-PDT, including intensive and maintenance treatment, over five years.
RESULTS: Symptoms and lesions were well controlled after 13 initial ALA-PDT sessions. However, the lesions recurred after ALA-PDT was discontinued and topical halometasone was introduced. The patient subsequently received further courses of ALA-PDT, bringing the total to 41 sessions. Lesions regressed following each treatment course. Adverse effects were mild and tolerable, and no severe adverse events were observed over the five-year period. No recurrence was noted during the one-year follow-up after the final treatment course.
CONCLUSIONS: This case suggests that repeated ALA-PDT may be an effective and well-tolerated option for the long-term management of refractory male genital LS. Therefore, this patient underwent multiple courses of ALA-PDT for a total of 41 sessions With each course of ALA-PDT, the lesions regressed again, and no significant adverse effects were observed over the five-year period. No recurrence was noted during the one-year follow-up after the final treatment course. This case indicated ALA-PDT may be a safe and effective option for the long-term management of male genital LS.